AbCellera Biologics

ABCLNasdaq Canada Health Care Biotechnology: Pharmaceutical Preparations

Market cap

$3.602 B

$11.12 -9.45%

Close of 6 Nov 2026

As of 6 Nov 2026, AbCellera Biologics (ABCL) has a market capitalization of $3.60B. Market cap measures the value of outstanding equity at market prices; company totals combine applicable share classes. Prices and market caps come from Nasdaq, with financial fundamentals from SEC filings. See sources and calculation details.

Revenue

$75.1M

#2582 by revenue

Earnings

-$146.4M

Loss-making

Shares outstanding

306,611,466

Latest filing cover page

P/E ratio

—

Cap ÷ net income

Biotechnology: Pharmaceutical Preparations, ranked by market cap

All 498 →

#62Acadia PharmaceuticalsACAD$3.65B
#63Organon & Co.OGN$3.63B
#64AbCellera BiologicsABCL$3.60B
#65Tango TherapeuticsTNGX$3.52B
#66Disc MedicineIRON$3.49B

Insiders buying

All insider buying →

3 open-market purchases by officers and directors of AbCellera Biologics, worth $975.2K. Grants and option exercises are excluded.

John S. Montalbano$110.3K
10,000 shares at $11.03 on 18 Aug 2026 · filed 18 Aug 2026
Michael R. Hayden$481.0K
46,387 shares at $10.37 on 12 Aug 2026 · filed 14 Aug 2026
Andrew BoothChief Financial Officer$383.9K
37,200 shares at $10.32 on 14 Aug 2026 · filed 14 Aug 2026

What if AbCellera Biologics were worth as much as…

Open the what-if tool →

Gold $28.2T

$87,176.26

Per share 7,840× higher

Bitcoin $1.53T

$4,716.96

Per share 424× higher

Apple $5.02T

$15,485.33

Per share 1,393× higher

Or at a round number

$5.00B $10.0B $20.0B $50.0B

Where these numbers come from

Share counts and financials for AbCellera Biologics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Read the methodology.